Page 220 - 2021_04-Haematologica-web

M.J. Kersten et al.
Disclosures
The study drug (BV) was provided for the study and the study was funded by Takeda. Takeda did not have any influence on the analysis of the data or the interpretation of the results. AH received consultancy fees, honoraria, and research funding from Millennium/Takeda. MJK: Millennium/Takeda: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Gilead: Honoraria; Kite Pharma: Honoraria; Novartis: Honoraria. FM: Janssen: Scientific Lectures; BMS: Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory com- mittees. PJL: Millennium/Takeda: Consultancy, Research Funding; Servier: Consultancy, Research Funding; Roche: Consultancy; BMS: Consultancy; Sandoz: Consultancy; Genmab: Consultancy. AD: Millennium/Takeda: Consultancy, Honoraria, Research Funding. PB: Millennium/Takeda: Honoraria, Research Funding, Scientific Advisory Board; Roche: Honoraria; BMS: Honoraria, Scientific Advisory Board; MSD: Honoraria, Scientific Advisory Board; Jansen: Honoraria. MH: Consultant/advisor: Roche, Takeda, Celgene, Genmab; Research support: Roche, Takeda, Celgene, Genmab, Novartis, Janssen, Incyte, Genentech. TG: Millennium/Takeda: Honoraria, Gilead, Roche, MSD. JMZ: Consultant/advisor: Gilead, Roche, Takeda; Honoraria: Gilead, Roche, Takeda, Janssen. DDJ: Consultant/advisor: Takeda. All remaining authors have declared no conflicts of interest.
Contributions
MJK and AH designed the study; all authors collected the data; JD, MLY and HvT analyzed the data; JD and MJK wrote the manuscript with contributions from all authors, who also interpreted the data, read, commented on, and approved the final version of the manuscript; DdJ and AD performed the central pathology review; JZ, CB, AA and RV organized and performed the central FDG-PET-CT review; MJK and AH supervised the study.
Acknowledgments
The authors would like to thank all patients who participated in the trial, the Transplant BRaVE-trial team of the Trial Office of the Amsterdam UMC, location AMC, for their efforts in trial management and central data management, and the members of the Data Safety and Monitoring Board. The authors thank Marjolein Spiering, Edith van Dijkman, the data managers, trial nurses, lab and pharmacy personnel for their essential assistance with collecting and managing the study data. The authors thank Prof. Dr. Otto S. Hoekstra and Drs. Gerben J.C. Zwezerijnen for reviewing discrepancies in the central FDG-PET-CT review and Nathalie Hijmering, HOVON Pathology Facility and Biobank for biopsy collection and support of central pathology review.
Funding
This work was supported by research funding from Takeda.
References
1. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-2071.
2. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone- marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993; 341(8852):1051-1054.
3. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065-1072.
4.Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemothera- py in relapsed and refractory Hodgkin lym- phoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005;16(1):116- 123.
5. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001; 97(3):616-623.
6. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resis- tant, chemotherapy programs improves event-free survival in patients with Hodgkin
lymphoma. Blood. 2012;119(7):1665-1670. 7. Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant func- tional imaging. Br J Haematol. 2010;
148(6):890-897.
8. Devillier R, Coso D, Castagna L, et al.
Positron emission tomography response at the time of autologous stem cell transplanta- tion predicts outcome of patients with relapsed and/or refractory Hodgkin's lym- phoma responding to prior salvage therapy. Haematologica. 2012;97(7):1073-1079.
9.Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lym- phoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(11):1646-1652.
10.Santoro A, Magagnoli M, Spina F, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35-41.
11. Labrador J, Cabrero-Calvo M, Perez-Lopez E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Ann Hematol. 2014;93(10):1745-1753.
12. Eichenauer DA, Aleman BMP, Andre M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv19-iv29.
13. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821.
14. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-
1) molecule, a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1-14.
15. Moskowitz AJ, Schröder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by aug- mented ifosfamide, carboplatin, and etopo- side for patients with relapsed and refracto- ry Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284-292.
16. LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40-48.
17. Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentux- imab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodkgin lymphoma. Biol Blood Marrow Transplant. 2015; 21(12):2136-2140.
18. Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30(4):612-620.
19. Broccoli A, Argnani L, Botto B, et al. First sal- vage treatment with bendamustine and brentuximab vedotin in Hodgkin lym- phoma: a phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer J. 2019; 9(12):100.
20.Herrera AF, Palmer J, Martin P, et al. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann
1136
haematologica | 2021; 106(4)